These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 30201920)
1. Targeting CD46 Enhances Anti-Tumoral Activity of Adenovirus Type 5 for Bladder Cancer. Do MH; To PK; Cho YS; Kwon SY; Hwang EC; Choi C; Cho SH; Lee SJ; Hemmi S; Jung C Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30201920 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers. Cho YS; Do MH; Kwon SY; Moon C; Kim K; Lee K; Lee SJ; Hemmi S; Joo YE; Kim MS; Jung C Oncotarget; 2016 Jun; 7(25):38210-38223. PubMed ID: 27203670 [TBL] [Abstract][Full Text] [Related]
3. Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells. Iguchi K; Sakurai F; Tomita K; Katayama K; Yamaguchi T; Kawabata K; Tagawa M; Kawabata M; Shirakawa T; Mizuguchi H Cancer Gene Ther; 2012 Feb; 19(2):118-25. PubMed ID: 22076042 [TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292 [TBL] [Abstract][Full Text] [Related]
5. CD46 represents a target for adenoviral gene therapy of malignant glioma. Ulasov IV; Tyler MA; Zheng S; Han Y; Lesniak MS Hum Gene Ther; 2006 May; 17(5):556-64. PubMed ID: 16716112 [TBL] [Abstract][Full Text] [Related]
6. Increased antitumor capability of fiber-modified adenoviral vector armed with TRAIL against bladder cancers. Zhao Y; Li Y; Wang Q; Wang L; Yang H; Li M Mol Cell Biochem; 2011 Jul; 353(1-2):93-9. PubMed ID: 21437625 [TBL] [Abstract][Full Text] [Related]
7. A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression. Cao W; Tian J; Li C; Gao Y; Liu X; Lu J; Wang Y; Wang Z; Svatek RS; Rodriguez R Virol J; 2017 Aug; 14(1):149. PubMed ID: 28789701 [TBL] [Abstract][Full Text] [Related]
8. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394 [TBL] [Abstract][Full Text] [Related]
9. Fiber-modified adenovirus-mediated suicide gene therapy can efficiently eliminate bladder cancer cells in vitro and in vivo. Wang DG; Zhao MJ; Liu YQ; Liu XW; Niu HT; Song YF; Tian YX Oncotarget; 2016 Nov; 7(44):71710-71717. PubMed ID: 27687590 [TBL] [Abstract][Full Text] [Related]
10. Targeted expression of herpes simplex virus thymidine kinase in adenovirus-infected cells reduces virus titers upon treatment with ganciclovir in vitro. Ibrišimović M; Nagl U; Kneidinger D; Rauch M; Lion T; Klein R J Gene Med; 2012 Jan; 14(1):3-19. PubMed ID: 22190534 [TBL] [Abstract][Full Text] [Related]
11. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Sachs MD; Rauen KA; Ramamurthy M; Dodson JL; De Marzo AM; Putzi MJ; Schoenberg MP; Rodriguez R Urology; 2002 Sep; 60(3):531-6. PubMed ID: 12350512 [TBL] [Abstract][Full Text] [Related]
12. Improved gene transfer into bladder cancer cells using adenovirus vector containing RGD motif. Hiwasa K; Nagaya H; Terao S; Acharya B; Hamada K; Mizuguchi H; Gotoh A Anticancer Res; 2012 Aug; 32(8):3137-40. PubMed ID: 22843884 [TBL] [Abstract][Full Text] [Related]
13. Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Parker AL; White KM; Lavery CA; Custers J; Waddington SN; Baker AH Gene Ther; 2013 Dec; 20(12):1158-64. PubMed ID: 24005577 [TBL] [Abstract][Full Text] [Related]
14. A fiber-modified adenovirus co-expressing HSV-TK and Coli.NTR enhances antitumor activities in breast cancer cells. Zhan Y; Yu B; Wang Z; Zhang Y; Zhang HH; Wu H; Feng X; Geng RS; Kong W; Yu XH Int J Clin Exp Pathol; 2014; 7(6):2850-60. PubMed ID: 25031704 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. Wang H; Liu Y; Li Z; Tuve S; Stone D; Kalyushniy O; Shayakhmetov D; Verlinde CL; Stehle T; McVey J; Baker A; Peng KW; Roffler S; Lieber A J Virol; 2008 Nov; 82(21):10567-79. PubMed ID: 18753195 [TBL] [Abstract][Full Text] [Related]
16. Loss of coxsackie and adenovirus receptor expression in human colorectal cancer: A potential impact on the efficacy of adenovirus-mediated gene therapy in Chinese Han population. Ma YY; Wang XJ; Han Y; Li G; Wang HJ; Wang SB; Chen XY; Liu FL; He XL; Tong XM; Mou XZ Mol Med Rep; 2016 Sep; 14(3):2541-7. PubMed ID: 27485384 [TBL] [Abstract][Full Text] [Related]
17. A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy. Yang M; Yang CS; Guo W; Tang J; Huang Q; Feng S; Jiang A; Xu X; Jiang G; Liu YQ Cancer Biol Ther; 2017 Nov; 18(11):833-840. PubMed ID: 29144842 [TBL] [Abstract][Full Text] [Related]
18. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223 [TBL] [Abstract][Full Text] [Related]